MG96077 is a novel, broad spectrum, non-beta-lactam beta-lactamase inhibitor designed to overcome beta-lactamase mediated antibiotic resistance. MG96077 exhibits a broad-spectrum inhibitory profile for both class A and class C beta-lactamase enzymes. In addition, the compound overcomes resistance in beta-lactam-resistant organisms such as Pseudomonas aeruginosa and Klebsiella pneumoniae.
MG96077 is in advanced preclinical development and ready to commence IND-enabling studies.
Worldwide rights to MG96077 are available for licensing.
Business Development Contacts
Jessica M. Corson, MBA
Director, Business Development
Mirati Therapeutics, Inc.
Tel: 858.332.3410 – email@example.com